Health

Telangana reports first case of Guillain-Barré Syndrome, 25-year-old woman in critical condition

Telangana reports first case of Guillain-Barré Syndrome, 25-year-old woman in critical condition

In what is being reported as the first case of Guillain-Barré Syndrome (GBS) in Telangana, a 25-year-old woman hailing from Siddipet district has been admitted to a private hospital in Hyderabad. Doctors have stated that her condition is critical, and she is currently on ventilator support.

The patient is currently admitted at KIMS Hospital in Hyderabad. According to Consultant Neurologist Dr. Praveen Kumar Yada, the patient has no history of travel to Pune, Maharashtra, where the disease has a relatively higher prevalence. Additionally, there is no known family history of the condition. “GBS occurs when the body’s immune system mistakenly attacks its own nervous system, often following fever or loose motions,” Dr. Yada explained.

The woman was initially treated at another hospital for a week, but as her condition deteriorated, she was transferred to KIMS Hospital for advanced medical care. Due to the severity of her symptoms, she remains entirely dependent on ventilator support.

Guillain-Barré Syndrome (GBS) is an autoimmune neurological disorder in which the body’s immune system mistakenly attacks the peripheral nerves, causing muscle weakness that can gradually progress to paralysis. The condition may develop over a few days or take several weeks to manifest. While it can affect individuals of any age, it is more commonly seen in adults and tends to occur more frequently in males.

Leave a comment

Your email address will not be published. Required fields are marked *

You may also like

Health

Sleepless nights? Here’s a drug to help Premium

  • December 26, 2024
Sleepless nights? Here’s a drug to help Premium (In the weekly Health Matters newsletter, Ramya Kannan writes about getting to
Health

Journal finally retracts the discredited hydroxychloroquine paper Premium

  • December 26, 2024
Journal finally retracts the discredited hydroxychloroquine paper Premium More than four-and-a-half years after the highly questionable “study” by a French researcher Didier